271 related articles for article (PubMed ID: 29859131)
1. "Exceptional brain aging" without Alzheimer's disease: triggers, accelerators, and the net sum game.
Vemuri P
Alzheimers Res Ther; 2018 Jun; 10(1):53. PubMed ID: 29859131
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals.
Vemuri P; Knopman DS; Lesnick TG; Przybelski SA; Mielke MM; Graff-Radford J; Murray ME; Roberts RO; Vassilaki M; Lowe VJ; Machulda MM; Jones DT; Petersen RC; Jack CR
JAMA Neurol; 2017 Jun; 74(6):718-726. PubMed ID: 28418521
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
4. Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies.
Lista S; Dubois B; Hampel H
J Nutr Health Aging; 2015 Feb; 19(2):154-63. PubMed ID: 25651440
[TBL] [Abstract][Full Text] [Related]
5. Brain Aging and Late-Onset Alzheimer's Disease: A Matter of Increased Amyloid or Reduced Energy?
Mecocci P; Baroni M; Senin U; Boccardi V
J Alzheimers Dis; 2018; 64(s1):S397-S404. PubMed ID: 29562513
[TBL] [Abstract][Full Text] [Related]
6. Multimodal Neuroimaging in Alzheimer's Disease: Early Diagnosis, Physiopathological Mechanisms, and Impact of Lifestyle.
Chételat G
J Alzheimers Dis; 2018; 64(s1):S199-S211. PubMed ID: 29504542
[TBL] [Abstract][Full Text] [Related]
7. A Novel Grading Biomarker for the Prediction of Conversion From Mild Cognitive Impairment to Alzheimer's Disease.
Tong T; Gao Q; Guerrero R; Ledig C; Chen L; Rueckert D; Initiative ADN
IEEE Trans Biomed Eng; 2017 Jan; 64(1):155-165. PubMed ID: 27046891
[TBL] [Abstract][Full Text] [Related]
8. Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.
Villemagne VL; Rowe CC
J Alzheimers Dis; 2013; 33 Suppl 1():S349-59. PubMed ID: 22710919
[TBL] [Abstract][Full Text] [Related]
9. Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.
Tan CH; Fan CC; Mormino EC; Sugrue LP; Broce IJ; Hess CP; Dillon WP; Bonham LW; Yokoyama JS; Karch CM; Brewer JB; Rabinovici GD; Miller BL; Schellenberg GD; Kauppi K; Feldman HA; Holland D; McEvoy LK; Hyman BT; Bennett DA; Andreassen OA; Dale AM; Desikan RS;
Acta Neuropathol; 2018 Jan; 135(1):85-93. PubMed ID: 29177679
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
[TBL] [Abstract][Full Text] [Related]
11. Sex differences in the association between AD biomarkers and cognitive decline.
Koran MEI; Wagener M; Hohman TJ;
Brain Imaging Behav; 2017 Feb; 11(1):205-213. PubMed ID: 26843008
[TBL] [Abstract][Full Text] [Related]
12. Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease.
Shah TM; Gupta SM; Chatterjee P; Campbell M; Martins RN
Mol Psychiatry; 2017 Mar; 22(3):353-363. PubMed ID: 28093567
[TBL] [Abstract][Full Text] [Related]
13. Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's disease?
Brown BM; Peiffer JJ; Martins RN
Mol Psychiatry; 2013 Aug; 18(8):864-74. PubMed ID: 23164816
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's disease (AD) therapeutics - 2: Beyond amyloid - Re-defining AD and its causality to discover effective therapeutics.
Mullane K; Williams M
Biochem Pharmacol; 2018 Dec; 158():376-401. PubMed ID: 30273552
[TBL] [Abstract][Full Text] [Related]
15. Neural substrates of cognitive reserve in Alzheimer's disease spectrum and normal aging.
Lee DH; Lee P; Seo SW; Roh JH; Oh M; Oh JS; Oh SJ; Kim JS; Jeong Y
Neuroimage; 2019 Feb; 186():690-702. PubMed ID: 30503934
[TBL] [Abstract][Full Text] [Related]
16. The Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer's Disease.
Hays CC; Zlatar ZZ; Wierenga CE
Cell Mol Neurobiol; 2016 Mar; 36(2):167-79. PubMed ID: 26898552
[TBL] [Abstract][Full Text] [Related]
17. Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors.
Takeda S
Neurosci Res; 2019 Apr; 141():36-42. PubMed ID: 30120962
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
[TBL] [Abstract][Full Text] [Related]
19. The Brain's Structural Connectome Mediates the Relationship between Regional Neuroimaging Biomarkers in Alzheimer's Disease.
Pandya S; Kuceyeski A; Raj A;
J Alzheimers Dis; 2017; 55(4):1639-1657. PubMed ID: 27911289
[TBL] [Abstract][Full Text] [Related]
20. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
